DARPins: An efficient targeting domain for lentiviral vectors

Molecular Therapy

Volumn 19, Issue 4, 2011, Pages 686-693

  Münch, Robert C ^a   Mühlebach, Michael D ^a   Schaser, Thomas ^a   Kneissl, Sabrina ^a   Jost, Christian ^b   Plückthun, Andreas ^b   Cichutek, Klaus ^a   Buchholz, Christian J ^a  

^a PAUL EHRLICH INSTITUT   (Germany)

^b UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANKYRIN; DESIGNED ANKYRIN REPEAT PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HEMAGGLUTININ; HYBRID PROTEIN; LENTIVIRUS VECTOR; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VIVO STUDY; LIVER; MOUSE; NONHUMAN; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN TARGETING; SPLEEN; VESICULAR STOMATITIS VIRUS; VIRAL GENE DELIVERY SYSTEM;

MEASLES VIRUS; VESICULAR STOMATITIS VIRUS;

EID: 79953331925     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2010.298     Document Type: Article

References (31)

1. Cockrell, AS and Kafri, T (2007). Gene delivery by lentivirus vectors. Mol Biotechnol 36: 184-204. (Pubitemid 350135911)
2. Naldini, L (2009). Medicine. A comeback for gene therapy. Science 326: 805-806.
3. Frecha, C, Szécsi, J, Cosset, FL and Verhoeyen, E (2008). Strategies for targeting lentiviral vectors. Curr Gene Ther 8: 449-460.
4. Buchholz, CJ, Mühlebach, MD and Cichutek, K (2009). Lentiviral vectors with measles virus glycoproteins - dream team for gene transfer? Trends Biotechnol 27: 259-265.
5. Morizono, K, Xie, Y, Ringpis, GE, Johnson, M, Nassanian, H, Lee, B et al. (2005). Lentiviral vector retargeting to P-glycoprotein on metastatic melanoma through intravenous injection. Nat Med 11: 346-352. (Pubitemid 40460565)
6. Morizono, K, Xie, Y, Helguera, G, Daniels, TR, Lane, TF, Penichet, ML et al. (2009). A versatile targeting system with lentiviral vectors bearing the biotin-adaptor peptide. J Gene Med 11: 655-663.
7. Morizono, K, Pariente, N, Xie, Y and Chen, IS (2009). Redirecting lentiviral vectors by insertion of integrin-tageting peptides into envelope proteins. J Gene Med 11: 549-558.
8. Yanagi, Y, Takeda, M and Ohno, S (2006). Measles virus: cellular receptors, tropism and pathogenesis. J Gen Virol 87(Pt 10): 2767-2779. (Pubitemid 44463885)
9. Funke, S, Maisner, A, Mühlebach, MD, Koehl, U, Grez, M, Cattaneo, R et al. (2008). Targeted cell entry of lentiviral vectors. Mol Ther 16: 1427-1436.
10. Anliker, B, Abel, T, Kneissl, S, Hlavaty, J, Caputi, A, Brynza, J et al. (2010). Specific gene transfer to neurons, endothelial cells and hematopoetic progenitors with lentiviral vectors. Nat Methods 7: 929-935.
11. Sedgwick, SG and Smerdon, SJ (1999). The ankyrin repeat: a diversity of interactions on a common structural framework. Trends Biochem Sci 24: 311-316. (Pubitemid 29366805)
12. Kohl, A, Binz, HK, Forrer, P, Stumpp, MT, Plückthun, A and Grütter, MG (2003). Designed to be stable: crystal structure of a consensus ankyrin repeat protein. Proc Natl Acad Sci USA 100: 1700-1705. (Pubitemid 36254511)
13. Binz, HK, Amstutz, P, Kohl, A, Stumpp, MT, Briand, C, Forrer, P et al. (2004). Highaffinity binders selected from designed ankyrin repeat protein libraries. Nat Biotechnol 22: 575-582. (Pubitemid 38590636)
14. Yarden, Y (2001). Biology of HER2 and its importance in breast cancer. Oncology 61 Suppl 2: 1-13. (Pubitemid 33033419)
15. Zahnd, C, Wyler, E, Schwenk, JM, Steiner, D, Lawrence, MC, McKern, NM et al. (2007). A designed ankyrin repeat protein evolved to picomolar affinity to Her2. J Mol Biol 369: 1015-1028. (Pubitemid 46754059)
16. Steiner, D, Forrer, P and Plückthun, A (2008). Efficient selection of DARPins with sub-nanomolar affinities using SRP phage display. J Mol Biol 382: 1211-1227.
17. Ramm, K, Gehrig, P and Plückthun, A (1999). Removal of the conserved disulfide bridges from the scFv fragment of an antibody: effects on folding kinetics and aggregation. J Mol Biol 290: 535-546. (Pubitemid 29324837)
18. Engelstädter, M, Bobkova, M, Baier, M, Stitz, J, Holtkamp, N, Chu, TH et al. (2000). Targeting human T cells by retroviral vectors displaying antibody domains selected from a phage display library. Hum Gene Ther 11: 293-303. (Pubitemid 30080387)
19. Dreier, B, Mikheeva, G, Belousova, N, Parizek, P, Boczek, E, Jelesarov, I et al. (2010). Her2-specific multivalent adapters confer designed tropism to adenovirus for gene targeting. J Mol Biol (epub ahead of print).
20. Bucheit, AD, Kumar, S, Grote, DM, Lin, Y, von Messling, V, Cattaneo, RB et al. (2003). An oncolytic measles virus engineered to enter cells through the CD20 antigen. Mol Ther 7: 62-72. (Pubitemid 36305359)
21. Jäger, M, Gehrig, P and Plückthun, A (2001). The scFv fragment of the antibody hu4D5-8: evidence for early premature domain interaction in refolding. J Mol Biol 305: 1111-1129. (Pubitemid 33027747)
22. Overbaugh, J, Miller, AD and Eiden, MV (2001). Receptors and entry cofactors for retroviruses include single and multiple transmembrane-spanning proteins as well as newly described glycophosphatidylinositol-anchored and secreted proteins. Microbiol Mol Biol Rev 65: 371-89, table of contents. (Pubitemid 32881711)
23. Buchholz, CJ, Schneider, U, Devaux, P, Gerlier, D and Cattaneo, R (1996). Cell entry by measles virus: long hybrid receptors uncouple binding from membrane fusion. J Virol 70: 3716-3723. (Pubitemid 26157351)
24. Moasser, MM (2007). The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene 26: 6469-6487. (Pubitemid 47530601)
25. Baselga, J and Swain, SM (2009). Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 9: 463-475.
26. Hasegawa, K, Hu, C, Nakamura, T, Marks, JD, Russell, SJ and Peng, KW (2007). Affinity thresholds for membrane fusion triggering by viral glycoproteins. J Virol 81: 13149-13157. (Pubitemid 350156953)
27. Zhang, KX, Kim, C, Chow, E, Chen, IS, Jia, W and Rennie, PS (2011). Targeting trastuzumab-resistant breast cancer cells with a lentivirus engineered to bind antibodies that recognize HER-2. Breast Cancer Res Treat 125: 89-97.
28. Stumpp, MT and Amstutz, P (2007). DARPins: a true alternative to antibodies. Curr Opin Drug Discov Devel 10: 153-159. (Pubitemid 46438644)
29. Zufferey, R, Nagy, D, Mandel, RJ, Naldini, L and Trono, D (1997). Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol 15: 871-875.
30. Demaison, C, Parsley, K, Brouns, G, Scherr, M, Battmer, K, Kinnon, C et al. (2002). High-level transduction and gene expression in hematopoietic repopulating cells using a human immunodeficiency [correction of imunodeficiency] virus type 1-based lentiviral vector containing an internal spleen focus forming virus promoter. Hum Gene Ther 13: 803-813. (Pubitemid 34493974)
31. Moll, M, Klenk, HD and Maisner, A (2002). Importance of the cytoplasmic tails of the measles virus glycoproteins for fusogenic activity and the generation of recombinant measles viruses. J Virol 76: 7174-7186. (Pubitemid 41246231)